Target intelligence / Profile preview

Concanavalin A (ConA)

Target
ConA
Molecular classification
Lectin, Carbohydrate-binding protein, Legume lectin family
01

Overview

Concanavalin A (ConA) is a well-characterized legume lectin derived from the jack bean, Canavalia ensiformis, belonging to the carbohydrate-binding protein family (UniProt: P02866). It is widely utilized in biological research due to its high affinity for alpha-D-mannosyl and alpha-D-glucosyl residues, which allows it to bind and cross-link various cell surface glycoproteins (Wikipedia). ConA is primarily recognized for its role as a potent T-cell mitogen, frequently used to stimulate lymphocyte proliferation and study immune signaling cascades in vitro. In pharmacology, it is the standard agent used to induce experimental autoimmune hepatitis in murine models, providing a platform to investigate T-cell-mediated liver injury and the role of inflammatory cytokines like TNF-alpha (NIH). While research has explored its potential anti-tumor effects through the induction of apoptosis and autophagy in cancer cells, its clinical application is severely limited by its high systemic toxicity and strong immunogenic profile. Its structural properties as a homotetramer at neutral pH make it a robust tool for glycoproteomics and the purification of glycosylated molecules (PubMed).

Other names
Jack bean lectinCon-ACana_Ensiformis_Lectin
02

Mechanism of action

Concanavalin A acts by specifically binding to alpha-D-mannosyl and alpha-D-glucosyl residues on cell surface glycoproteins, leading to the cross-linking of surface receptors (such as the T-cell receptor) and the subsequent activation of intracellular signaling pathways that drive mitogenesis or programmed cell death (PubMed).

03

Biological functions

T-cell activationMitogenesisCell agglutinationApoptosis inductionAutophagy inductionGlycoprotein binding
04

Disease associations

Autoimmune hepatitis (experimental model)Cancer (preclinical research)Infection (research tool for viral entry)
05

Safety considerations

Severe hepatotoxicitySystemic inflammatory responseImmunogenicityPotential for cytokine storm
06

Interacting drugs

Methyl alpha-D-mannopyranoside

2 more in the full profile.

07

Biomarkers

Alanine aminotransferase (ALT)Aspartate aminotransferase (AST)Interferon-gamma (IFN-g)Tumor necrosis factor-alpha (TNF-a)

Beyond the preview

Go deeper on Concanavalin A (ConA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concanavalin A (ConA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call